Applications

1778 – Fibroblast growth factor 23 (FGF-23) testing for patients with a high pre-test probability of X-linked hypophosphatemia (XLH) to determine eligibility for burosumab on the Pharmaceutical Benefits Scheme (PBS)

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Analysis of plasma or serum fibroblast growth factor 23 (FGF-23) for patients with a high pre-test probability of X-linked hypophosphatemic rickets to determine eligibility for burosumab.

Type: Investigative technology

Medical condition this application addresses

Hypophosphatemic rickets is a condition in which, due to abnormal excess production of an endocrine hormone FGF23, there is excessive loss of phosphate in the urine that results in low serum phosphate.

Because phosphate is an essential element in the formation of hydroxyapatite, the mineral that deposits on osteoid protein to produce a rigid skeleton, low phosphate levels produce under mineralisation of the skeleton, a condition called rickets or osteomalacia.

A small number of individuals, perhaps 300 in Australia, have developed osteomalacia because of phosphate deficiency due to excessive FGF23 production. In over 80% of cases this is due to an inactivation mutation in the PHEX gene that is an important negative regulator of the production of FGF23.

Consultation survey and deadlines

  • MSAC consultation: Closed Friday 14 June 2024

Meetings to consider this application

  • PASC meeting: Expedited – bypassing PASC
  • ESC meeting: Expedited – bypassing ESC
  • MSAC meeting: 1–2 August 2024